LUPRON: MEMORY LOSS AND COGNITIVE DYSFUNCTION

In February, 1992, three pharmacists reported the results of a telephone survey they conducted among 16 women who had taken a GnRH analogue, (not Lupron), over the previous 4 months.(1) The survey found that “56% reported some type of memory difficulty.”(1) The survey was instituted after a 30-year-old woman reported short-term-memory loss approximately one month after she was prescribed a GnRH analogue. “Several days later, another patient reported a similar occurrence.”(1) The pharmacists “conducted a MEDLINE search of possible memory impairment associated with GnRH analogs, estrogen deficiency, and menopause and were unable to retrieve any further documentation.” When the pharmacists contacted the manufacturer, “a search of their computerized worldwide database” was able to locate ONLY 3 “reports of poor memory or memory loss that were possibly drug related.” (1) This is quite a discrepancy from the pharmacists’ findings of 56% reporting some type of memory difficulty. “The memory impairment was described by the women as memory loss, poor memory, forgetfulness, and concentration problems.”(1) One woman (of the 16) “recounted her experience of driving down a street and stopping at a stop light but not being able to remember why she was at the stop light (she no longer drives alone).”(1)

In July, 1992, Dr. Andrew Friedman and colleagues reported memory loss in the medical literature. They stated that “two of the most disturbing adverse effects experienced by women receiving Leuprolide Acetate were depression and short-term memory loss.” (2)

In 1993, Dr. Varney and colleagues reported the effects of Lupron on 18 women taking Lupron for infertility treatment.(3) Dr. Varney decided “to focus on possible problems as reported by prior patients.” (3) According to Dr. Varney, patients regularly reported “poor memory and or clumsiness” on Lupron and “of particular interest were memory and coordination, as these were commonly observed patient complaints.” (3)

Dr. Varney found that “a significant proportion of women, more than half in some cases, showed significantly worse performance on one or more memory tests while on leuprolide acetate. When memory test performances were combined, a substantial majority of the patients [72%showed difficulty with memory while on leuprolide acetate.”(3) (See table below) “Some individuals showed significant cognitive deficits” while on Lupron “particularly in the area of memory, fine motor coordination and two-point discrimination.”(3) Dr. Varney also found that 50% of the women showed a 42.7% decline from baseline in fine motor coordination on Lupron, and, 22% of the women showed a 16.6% decline in gross motor performance.(3) (See table below) 

Dr. Varney’s study also found that 11% of the women taking Lupron showed more severe disturbances in cognitive function. (3) “In these cases, symptoms included episodic memory gaps, spells of aphasia, episodic problems with confusion, and brief dramatic changes in emotional tone. In addition, these women showed episodes of occasional sensory illusions in the auditory, visual, olfactory, or somatosensory spheres” of the brain.(3) “In each case the patient and others had noted significant lapses in their work and they were able to accomplish work for which they had no recollection.”(3) “Memory gaps and other problems impaired them in activities of daily living, safe operation of motor vehicles, and vocational activities.”(3) One of the 18 patients, in particular, had a drop in IQ from 135 to 117.(3)

In 1996, Dr. Newton and colleagues studied the effect of GnRH agonists on memory in 16 women. Dr. Newton concluded that memory functioning decreased during GnRH-a administration and “prospective memory was most affected.” (4) Dr. Newton stated that “the mechanism by which memory is affected remains unclear but the hypothesis that psychological factors” that “could account for complaints was not supported.” In addition, “impairment was not related to excessive health concerns or mood changes.” According to Dr. Newton, 11% of the women without memory complaints prior to taking a GnRH-a continued to report memory problems 6 months after stopping the GnRH-a.(4)

Dr. Newton also concluded that “memory disruption may be a more common side effect of GnRH-a treatment than currently is recognized.” “By the final week of treatment, women reported greater memory complaints than a community sample of similar age. He found that 75% experienced memory problems on a GnRH agonist. “Thirty-one percent [31%] had ‘mild’ complaints, (0 to 1 SD greater than the community mean), 25% had ‘moderate’ complaints (1 to 2 SD greater than the mean) and 19% had ‘marked’ complaints (greater than or equal to 2 SD greater than the mean).” Women also reported an increase in sour taste and numbness. (4)

The medical literature states that most people first experience cognitive disorders while on Lupron; not 5 or 10 years after stopping the drug. Yet, it took the medical community nearly 10 years to publish an article stating that Lupron even causes cognitive disorders. In 1993, Dr. Varney stated that “there was NO correlation between estradiol levels and test results on any test.”(3) In 1993, Dr. Friedman stated that the mechanism by which short-term memory loss occurs is “unclear”(2) In 1996, Dr. Newton stated that “the mechanism by which memory is affected remains unclear.” From the above statements it is obvious that these doctors did not feel that the cognitive problems experienced by these women on Lupron were due to lack of estrogen and/or menopause.

The mechanism by which Lupron causes memory loss, episodic memory gaps, spells of aphasia, episodic problems with confusion, amnesia, difficulty thinking/concentrating, drops in IQ, problems with fine/gross motor coordination, and other cognitive problems, needs to be addressed. Most people occassionally forget a name, where they put their keys, or which aisle they parked their car at an amusement park. That is not what we are talking about with Lupron. Instead we are talking about pharmacists who stated that 1 of the 16 women they interviewed “recountered her experience of driving down a street and stopping at a stop light, but not being able to remember why she was at the stop light (she no longer drives alone).” (1) We are talking about a doctor who found that 1 of the 18 patients he studied had a drop in IQ from 135 to 117. (3) We are talking about a doctor who found that 50% of the women he studied showed a 42.7% decline from baseline in fine motor coordination on Lupron, and, 22% of the women showed a 16.6% decline in gross motor performance.(3) We are talking about a doctor who reported that 11% of the women taking Lupron showed more severe disturbances in cognitive function. (3) We are talking about patients who had “significant lapses in their work and they were able to accomplish work for which they had no recollection.” (3) Episodic memory gaps, spells of aphasia, episodic problems with confusion, amnesia, difficulty thinking/concentrating, drops in IQ, problems with fine/gross motor coordination, and other cognitive problems, have impaired many people on Lupron in activities of daily living, safe operation of motor vehicles, and vocational activities. This is more than occassionally forgetting a name, where you put you keys, or which aisle you parked your car in at an amusement park.

LUPRON: ADVERSE REACTIONS REPORTED

LUPRON: ADVERSE REACTIONS REPORTED
FOR WOMEN

 

265 different adverse reactions are listed in the package insert for Lupron

 

By 1999, the FDA had received over 6,000 adverse reaction reports for Lupron“In an article in the Journal of the American Medical Association, then FDA Commissioner David A. Kessler revealed that ‘only about 1% of serious events are reported to the FDA.'” (1)

 

REPORTING TO THE FDA IS TOTALLY VOLUNTARY:
If your doctor believes/knows that a medical condition was CAUSED by a drug s/he is NOT REQUIRED to report it to the FDA.
Several years ago the American Medical Association fought a hard battle to ensure that reporting to the FDA REMAINS VOLUNTARY. That is, even if the doctor believes/knows that a drug CAUSED a medical problem, the AMA DID NOT WANT doctors to be REQUIRED to report the information to the FDA.

 

The package insert does NOT state that ALL medical problems CAUSED BY LUPRON will GO AWAY when YOU STOP TAKING Lupron

 

Listed below are SOME of the adverse reactions/symptoms/diagnoses that have been reported and/or are associated with the use of Lupron.
The adverse reactions/symptoms/diagnoses include those reported:

  1. in the package insert (*) which can be found in the book the Physicians Desk Reference (PDR) in any library
  2. to the FDA (+) as part of the Spontaneous Reporting System/Division of Epidemiology and Surveillance (MedWatch Report Forms)
  3. in the medical literature (#).

Only side effects/conditions that have been REPORTED to the FDA, or in the medical literature, or in the package insert are included in the list below.
Side effects/conditions that have been ATTRIBUTED to Lupron but have NOT BEEN REPORTED are NOT INCLUDED.

If “#” is the ONLY symbol present, then the symptom/diagnosis was ONLY reported in the medical literature and was NOT reported to the FDA. Even though it is possible to report findings in the medical literature to the FDA this information was NEVER reported to the FDA.

 

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | R | S | T | U | V | W-Z

 

A Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
13.5% Decrease in
Vertebral Trabecular Bone Density
(with 6 months of the 3.75 mg per month Depot)
*
Ab(dominal) Enlargement +
Ab(dominal) Synd(rome) Acute +
Abortion +
Abscess at the Inject(ion) Site * +
Abscess Periodontal +
Acne * + #
Adenoma +
Adren(al) Insuffic(iency) +
Agitation * +
Albuminuria +
Alopecia * +
Allerg(ic) React(ion) +
Altered Hormone Level +
Amblyopia +
Amenorrhea +
Amnesia +
Amylase Inc(rease) +
ANA +
Anaphylactoid Symptoms *
Anaphyl(axis) +
Androgen-like Effects
*
Anemia +
Anemia Aplastic +
Anemia Hemol(ytic) DOP +
Anemia Hypochrom(atic) +
Anemia Iron Defic(iency) +
Angina Pectoris +
Angioedema +
Anisocoria +
Anomaly Congen(ital) +
ASD
Cardiac Problem [Unspecified]
Coarction of the Aorta
Enlarged Liver
Enlarged Spleen
Growth Retardation
Hyperplastic Aortic Isthmus
Imperforate Anus
Rectovaginal Fistula
Spinal Fusion
Spinal Muscular Atrophy
Thirteen Ribs
Underdeveloped Brain
Anomaly Vascul +
Anorexia +
Anxiety * +
Apnea +
Appetite Changes *
Appetite Inc(rease) +
Applicat(ion) Site React(ion) +
Arrhythmia +
Arthralgia +
Arthralgias/Myalgias #
Arthritis +
Arthritis Rheu(matoid) +
Arthrosis +
Ascites +
Asthenia * +
Asthma * +
Ataxia +
Atrophy Breast +
Atrophy Inject(ion) Site +
Atrophy Muscle +
Atrophy Skin +
AV Block SD +
B Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Bilirubinemia + +
Bleed(ing) Time Inc(rease) +
Blind Color +
Blood Test Changes:
Albumin Increase *
Alkaline Phosphatase Increase *
Bilirubin Increase *
BUN Increase *
Calcium Increase *
Creatinine Increase *
Glucose Increase *
HDL cholesterol Decrease *
HDL cholesterol Increase *
LDH Increase *
LDL cholesterol Increase *
LDL/HDL ratio Increase *
Neutrophil Decrease *
Phosphorus Increase *
Platelet Count Decrease *
Total Cholesterol Increase *
Total Protein Increase *
Transamine Increase *
Triglyceride Increase *
Uric Acid Increase *
WBC Decrease *
Blurred Vision #
Body Odor
* +
Bone Dis(order)
+
Bone Fracture Spontaneous
+
Bradycardia
+
Brain Synd(rome) Acute
+
Breast Changes
*
Breast Disorders
*
Breast Engorge(ment) +
Breast Enlarge(ment)
+
Breast Fibrocyst(ic)
+
Breast Pain
*
Breast Size Reduction
*
Breast Tenderness
*
Bronchitis
+
BUN Inc(rease)
+
C Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Capill(ary) Fragil(ity) Inc(rease) +
Carcinoma [Cancer] +
Carcinoma [Cancer] Breast +
Carcinoma [Cancer] Cervix +
Carcinoma [Cancer] Endometr(ium) +
Carcinoma [Cancer] Skin +
Carcinoma [Cancer] Thyroid +
Cardiomegaly +
Cardiovasc(ular) Dis(order) +
Cataract +
Cellulitis +
Cerebrovasc(ular) Accid(ent) +
Cerebrovasc(ular) Dis(order) +
Cervix Disorder *
Chills +
Chills/Fever +
Chloasma +
Cholecyst(itis) +
Chondrodyst(rophy) [Dwarfism] +
Chromosome Abnormality +
Colitis +
Colitis Ulcer(ative) +
Collagen Dis(order) +
Coma +
Confus(ion) * +
Conjunctivitis * +
Constipation +
Convuls(ions) +
Convul(sions) Grand Mal +
Corneal Lesion +
Coronary Art(ery) Dis(ease) +
Cough Inc(rease) +
Cramps Legs +
Creatine PK Inc(rease) +
Creatinine Inc(rease) +
Cyanosis +
Cyst +
Cystitis +
D Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Deaf +
Deaf Trans(itory) +
Death +
Decrease in IQ #
Decreased Appetite #
Decreased WBC *
Dehydration +
Delusions *
Depersonal(ization) +
Depression * + #
Depression/Psychotic +
Derm(atitis) Contact +
Derm(atitis) Exfol(iative) +
Derm(atitis) Lichen +
Diabetes Mell(itus) +
Diarrhea +
Diarrhea Bloody +
Dizziness * +
Dream Abn(ormality) +
Drug Inter(action) +
Dry Eye +
Dry Mouth * +
Dysmenorrhea +
Dyspareunia +
Dyspepsia +
Dysphagia +
Dyspnea +
Dysuria * +
E Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Ecchymosis * +
ECG Abnorm(ality) +
Eczema +
Edema * +
Edema Face * +
Edema General +
Edema Inject(ion) Site +
Edema Labia +
Edema Larynx +
Edema Peripheral +
Edema Tongue +
Effus(ion) Pleural +
Electrolyte Deplet(ion) +
Embolism Pulmonary * +
Emotion(al) Labil(ity) * +
Encephalopathy +
Endometr(ial) Dis(order) +
Enzyme Abnorm(ality) +
Eosinophilia +
Epiderm(al) Necro(sis) +
Epistaxis +
Erupt(ion) Fixed +
Erythema Mult(iforme) +
Erythema Nod(osum) +
Esophagitis +
ESR [Elevated Sedimentation Rate] Inc(rease) +
Euphoria +
Exophthalmus +
Extrapyr(amidal) Synd(rome) +
Extrasystoles +
Extrasystoles Vent +
Eye Dis(order) +
F Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Fatigue #
Fever +
Fibrillat(ion) Vent(ricular) +
Fibromyalgia *
Fibro(sis) Lung +
Flatul(ence) +
Flu Syndrome * +
Furunculosis +
G Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Gait Abnorm(ality) +
Gastritis +
Gastro Intestinal Disorder * +
Gastroenteritis +
GGTP Inc(rease) +
G I Disturbances *
Gingivitis +
Glaucoma +
Glossitis * +
Glycosuria +
Goiter +
Gonadotr(opin) Inc(rease) +
Gonadotr(opin) Inc(rease) FSH +
Gonadot(ropin) Inc(rease) LH +
Gout +
Granuloma +
Guillain Barre Syndrome +
Gynecomastia/Breast Disorders *
H Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Hair Dis(order) * +
Hair Discolor(ation) +
Hair Loss #
Halitosis +
Hallucin(ation) +
Hangover +
HDL Decrease *
Headache * + #
Headache Vasc(ular) +
Heart Arrest +
Heart Failure Right +
Hem(e) +
Hem(e) G(astro) I(ntestinal) +
Hem(e) Gum +
Hem(e) Inject(ion) Site +
Hem(e) Rectal +
Hem(e) Uter(us) +
Hem(e) Vaginal +
Hematemesis +
Hematuria +
Hemiplegia +
Hepatitis +
Hernia +
Herpes Simplex +
Herpes Zoster +
Hirsutism * +
Hostility +
Hot Flashes * #
Hot Flushes #
Hyper GUM +
Hyperacusis +
Hypercalcemi(a) +
Hypercholesterem(ia) +
Hyperesthesia +
Hyperglycem(ia) +
Hyperkalem(ia) +
Hyperkinesia +
Hyperlipem(ia) +
Hyperphosphatem(ia) +
Hypertens(ion) +
Hyperthyr(oid) +
Hypertonia +
Hyperventilation +
Hypesthesia * +
Hypoglycem(ia) +
Hypoglycem(ic) React(ion) +
Hypokinesis +
Hyponatrem(ia) +
Hypotension * +
Hypotension Post(ural) +
Hypothyroid +
Hysn +
Hysn Inject(ion) Site +
I Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Inability to Urinate #
Incontin(ence) Urin(ary) +
Increased Cholesterol Levels *
Increased Triglycerides *
Induration at the Injection Site *
Infarct Myocard(ial) +
Infect(ion) +
Infect(ion) Bact(erial) +
Infect(ion) Urin(ary) Tract +
Inject(ion) Site Abscess * +
Inject(ion) Site Atrophy +
Inject(ion) Site Edema +
Inject(ion) Site Fibro(sis) +
Inject(ion) Site Hem(e) +
Inject(ion) Site Hysn +
Injection Site Induration *
Inject(ion) Site Inflam(mation) +
Inject(ion) Site Mass +
Inject(ion) Site Pain +
Inject(ion) Site React(ion) * +
Insomnia * + #
Intracran(ial) Hypertens(ion) +
Ischemia Cerebral +
J Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Joint Dis(order) * +
Joint Pain * #
Joint Pain: Elbows #
Joint Pain: Costochondrals #
Joint Pain: Knees #
Joint Pain: Ankles #
Joint Pain: Metacarpals #
Joint Pain: Metatarsals #
Joint Pain: Shoulder #
K Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Keratoconjunctivitis +
Ketosis +
Kidney Calculus +
Kidney Fail(ure) +
Kidney Func(tion) Abnorm(ality) +
L Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Lab Test Abnorm(ality) +
Lacrimation Dis(order) +
Lactation Fem(ale) * +
Laryngismus +
Laryngitis *
LDH Inc(rease) * +
LE [Lupus Erythematous] Synd(rome) +
Leukemia +
Leukemia: Chronic Monocytic +
Leukocytosis +
Leukoderma(titis) +
Leukopenia +
Leukoplakia Genit(al) +
Leukoplakia Oral +
Leukorrhea +
Libido Decrease * + #
Libido Increase + #
Lipase Inc(rease) +
Lipodystrophy +
Liver Damage Aggr(avation) +
Liver Fail(ure) +
Liver Fatty +
Liver Func(tion) Abnorm(ality) +
Lung Dis(order) +
Lung Func(tion) Dec(rease) +
Lymphadenopathy * + #
Lymphoma Like React(ion) +
M Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Malaise +
Manic React(ion) +
Marrow Depression +
Mastalgia #
Mastitis +
Melanoma Skin +
Melanosis +
Melena +
Memory Disorder *
Memory Loss #
Memory Loss Short-Term #
Meningitis +
Menopause +
Menorrhagia +
Menorrhagia/Hypermenorrhea #
Mens(trual) Dis(order) * +
Metrorrhagia +
Migraine +
Monilia(sis) +
Monilia(sis) Oral +
Mood Lability #
Mood Swings *
Movement Dis(order) +
Multiple Sclerosis +
Myalgia * + #
Myasthenia +
Mydriasis +
Myocarditis +
Myopathy +
Myositis +
N Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Nail Disorder *
Nausea +
Nausea/Vomit * +
Nausea/Vomit/Diarr(hea) +
Neck Rigid +
Necro(sis) +
Necro(sis) Bone +
Necro(sis) Skin +
Necrotizing Myopathy +
Neoplasia +
Neoplasia Breast +
Neopl(asm) +
Neopl(asm) Breast +
Neopl(asm) CNS [Central Nervous System] +
Neopl(asm) Liver +
Neopl(asm) Uter(us) +
Nephritis +
Nephrosis +
Nervousness * +
Neuralgia +
Neuritis +
Neuritis/Optic +
Neuritis Periph(eral) +
Neuromuscular Disorders *
Neuropathy +
Neurosis +
Nocturia +
Nodule Skin +
O Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Obstruct(ion) Intest(inal) +
Opthalmitis +
Opthalmologic Disorders *
Osteoporosis +
Otitis Ext(ernal) +
Otitis Media +
Ovarian Cysts #
Ovarian Dis(order) +
Ovulation Fail(ure) +
P Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Pain +
Pain Abdo(minal) +
Pain Back +
Pain Bone +
Pain Breast +
Pain Chest +
Pain Chest Substern(al) +
Pain Ear * +
Pain Eye +
Pain General *
Pain Inject(ion) Site +
Pain Kidney +
Pain Muscle *
Pain Neck +
Pain Pelvic +
Pain Urethra +
Pallor +
Palpitations * +
Pancreatitis +
Pap Smear Susp +
Papilledema +
Paralysis * +
Paralysis Facial +
Paranoid Reaction +
Paresthesias * +
Paresth(esia) Circumoral +
Parathyr(oid) Dis(order) +
Parotid Enlarge(ment) +
Peripheral Edema #
Peripheral Neuritis +
Peripheral Neuropathy *
Perivascular Dermatitis +
Person(ality) Dis(order) * +
Petechia +
Pharyngitis +
Phleb(itis) +
Phosphatase Alkaline Inc(rease) +
Photophobia +
Photosensitivity * +
Platelet Abnorm(ality) +
Pleural Dis(order) +
Pneumonia +
Polyuria +
Pregnancy Dis(order) +
Pregnancy Test False Positive +
Pregnancy Unintend(ed) +
Prolactin Inc(rease) +
Prothrombin Dec(rease) +
Pruritus +
Pseudotumor Cerebri #
Psychosis +
Ptosis +
Pupil Dilation +
Pupil Dis(order) +
Purpura +
Pyelonephritis * +
R Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Rash * +
Rash Mac(ular) Pap(ular) +
Rash Petech(ia) +
Rash Pust(ular) +
Rash Vesic(ular) Bull(ous) +
React(ion) Aggr(avated) +
React(ion) Aggr(avated) +
Rectal Dis(order) +
Refract Dis(order) +
Respirat(ion) Dis(order) +
Respiratory Disorders +
Retinal Dis(order) +
Rhinitis * +
S Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Saliva Inc(rease) +
Salivary Gland Enlarge(ment) +
Salpingitis +
Sarcoma +
Scleritis +
Seborrhea +
Serum Sickness +
Sexual Maturity Female Accelerated +
SGOT Inc(rease) * +
SGPT Inc(rease) +
Shock +
Shortness of Breath *
Sinusitis +
Skin Dis(order) +
Skin Discolor(ation) +
Skin Dry +
Skin Reactions *
Skin Striae +
Sleep Disorder * +
Somnolescence +
Speech Disorder +
Spinal Fracture *
Stillbirth +
Stomatitis +
Stomatitis Aphth(ous) +
Stomatitis Ulcer +
Stridor +
Stupor +
Sudden Death +
Suicidal Ideation *
Suicide Attempt * +
Sweat * +
Syncope * +
T Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Tachycardia * +
Tachycardia Supervent(ricular) +
Taste Pervers(ion) * +
Tendon Dis(order) +
Tenesmus +
Tenosynovitis +
Tenosynovitis-like symptoms *
Thinking Abnorm(ality) +
Thirst * +
Thrombocythemia +
Thrombocytopenia +
Thrombophleb(itis) +
Thrombophleb(itis) Deep +
Thromboplastin Dec(rease) +
Throm(bosis) +
Throm(bosis) Art(erial) +
Throm(bus) Coronary +
Throm(bosis) Retinal Vein +
Throm(bus) +
Thyr(oid) Dis(order) +
Thyroiditis +
Tinnitus +
Tooth Caries +
Tooth Dis(order) +
Tremor +
Twitch +
U Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Ulcer Duoden(al) +
Ulcer Mouth +
Ulcer Skin +
Ulcer Stomach Hem(e) +
Urin(ary) Abnorm(ality) +
Urin(ary) Freq(uency) +
Urin(ary) Retent(ion) +
Urticaria [Hives] * +
Uter(ine) Fib(roid) Enlarge(ment) +
Uveitis +
V Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
Vaginal Bleeding *
Vaginal Discharge *
Vaginal Dryness * #
Vaginitis * +
Vasc(ular) Dis(order) +
Vasc(ular) Dis(order) Peripheral +
Vasculitis
Vasodilat(ion) +
Vertigo +
Vein Varicose +
Vertigo +
Vestibul(ar) Dis(order) +
Vis(ual) Field Defect +
Vision Abnorm(ality) +
Vitreous Dis(order) +
Voice Alterat(ion) +
Vomiting * +
Vulvovaginitis +
W-Z Reported in
1999 PDR
(Package Insert)
Reported
to the
FDA
Reported
in the
Medical
Literature
WBC [White Blood Cell] Abnormality +
Weight Changes *
Weight Dec(rease) +
Weight Inc(rease) +
Weight Gain/Loss *
Withdrawal Synd(rome) +

REFERENCES

BACKGROUND

THE NATIONAL LUPRON VICTIMS NETWORK is an independent, international, grass-roots organization comprised of men and women who have taken Lupron and are experiencing medical problems after stopping the drug. Founded in 1993, The National Lupron Victims Network includes members from the United States, Canada, Europe and other countries. Thousands of people have contacted the network.
Numerous people are experiencing similar chronic medical problems after exposure to Lupron. Most are having difficulties in obtaining satisfactory medical care to address these problems, even when they are listed as adverse reactions for Lupron. The National Lupron Victims Network is involved with all issues relevant to those who have taken Lupron and continue to experience medical problems as a result of Lupron usage.

REGISTRY

If you TOOK Lupron, and you are NOT on Lupron NOW, and you would like to be included in The National Lupron Victims Network’s Registry you can register online.

LUPRON INFORMATION

Most of the information that The National Lupron Victims Network provides comes from the medical literature written by doctors in peer reviewed medical journals. Some information comes from documents released by the US Food and Drug Administration, and the package insert. The package insert for Lupron is in the book The Physician’s Desk Reference, which can be found in most libraries.
None of the statistics provided by The National Lupron Victims Network comes from people who have contacted the organization.
All of the information provided by The National Lupron Victims Network is available through this internet site (of course for free!). The National Lupron Victims Network does NOT accept money from drug companies or other sources. We feel this would be a conflict of interest.

Lupron Petition & More

 

  • It has come to our attention that some people are making false claims about lawsuits, petitions, the National Lupron Victims Network, and other issues.
    We urge you to be cautious. (See information below.)
  • There are many sites on the internet that are meant to promote Lupron or appear friendly to members of The National Lupron Victims Network.
    The manufacturer of Lupron owns several sites on the internet, all with different web addresses.
    Other sites may be owned by organizations, or started by members of organizations, that are heavily funded by the manufacturer and are meant to attract members of The National Lupron Victims Network.
  • Be cautious of people who want you to e-mail them privately. These notes may read “e-mail me for information” or “want to hear your lupron experience.” You do not know who you are e-mailing.
  • Some websites have links to The National Lupron Victims Network’s website. It should be noted that a link to our site does not mean that we endorse the web site.
  • The websites from The National Lupron Victims Network always begin with
    http://www.lupronvictims.com

Slick Lines Used By PRO-Lupron People

If someone tells you that … Lupron should be a matter of “CHOICE”… you are hearing a slick PRO-Lupron line.
That statement really means that Lupron should remain on the market whether or not Lupron is safe, and/or whether or not Lupron works.
It really means that safety problems with Lupron should NOT be explored.
It really means that even if Lupron is unsafe, Lupron should still remain on the market.
If someone wants Lupron to be a CHOICE, they want Lupron to remain ON the market! They do not want Lupron taken OFF the market.

Where did the word “choice” come from?

ome examples:
1989 Brochure: Advanced Prostate Cancer Treatment and Choices
“Ultimately, the choice of therapy for prostate cancer is up to each individual.”
1993 Brochure: Your Choice For Treating Endometriosis
“… the drug you and your doctor have chosen…”
“Your treatment choice.”
“The treatment you and your doctor have chosen…”
1994 Brochure: Endometriosis
“Ultimately, the choice of treatment for endometriosis is up to each individual woman.”
“Whatever treatment a woman chooses…”
“…a treatment choice should be pursued with confidence.”
1994 Brochure: Coping With Endometriosis
“Ultimately, the best treatment choice is up to each individual and her physician.”